HOME > TOP STORIES

TOP STORIES

REGULATORY MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing

November 26, 2020
REGULATORY 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”

November 26, 2020
REGULATORY MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine

November 26, 2020
REGULATORY Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed

November 25, 2020
ACADEMIA Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL

November 25, 2020
BUSINESS Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake

November 24, 2020
REGULATORY 1st Humira Biosimilar to Join NHI Price List on Nov. 25

November 24, 2020
BUSINESS Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally

November 20, 2020
ORGANIZATION EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul

November 19, 2020
ACADEMIA National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors

November 18, 2020
REGULATORY Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review

November 17, 2020
REGULATORY With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly

November 16, 2020
REGULATORY “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister

November 16, 2020
BUSINESS Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?

November 13, 2020
BUSINESS New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO

November 12, 2020
REGULATORY Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18

November 11, 2020
BUSINESS Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals

November 11, 2020
BUSINESS Incyte Gearing Up for Solo Marketing in Japan, Set to Double Workforce to 70 Staffers

November 10, 2020
REGULATORY Japan to Set New Technical Fee for CureApp’s Quit Smoking App

November 10, 2020
BUSINESS Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020

November 9, 2020

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…